A

Alvotech SA
NASDAQ:ALVO

Watchlist Manager
Alvotech SA
NASDAQ:ALVO
Watchlist
Price: 5.415 USD 2.36%
Market Cap: $1.6B

Operating Margin

7.6%
Current
Improving
by 224%
vs 3-y average of -216.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
7.6%
=
Operating Income
$43.4m
/
Revenue
$573.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
7.6%
=
Operating Income
$43.4m
/
Revenue
$573.4m

Peer Comparison

Country Company Market Cap Operating
Margin
LU
Alvotech SA
NASDAQ:ALVO
1.7B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in Luxembourg
Percentile
57th
Based on 216 companies
57th percentile
7.6%
Low
-1 481.3% — 1.7%
Typical Range
1.7% — 12.1%
High
12.1% — 347.7%
Distribution Statistics
Luxembourg
Min -1 481.3%
30th Percentile 1.7%
Median 6.5%
70th Percentile 12.1%
Max 347.7%

Alvotech SA
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

In the fiercely competitive world of pharmaceuticals, Alvotech SA has carved out a distinct niche as a specialist in developing biosimilars—essentially highly similar alternatives to already approved biological medicines. Based in Iceland, the company was founded by Robert Wessman, renowned for his successful ventures in the pharmaceutical industry. Alvotech strives to not only make crucial medications more accessible but to also alleviate the strain of high drug costs on healthcare systems worldwide. With its ardent focus on quality and efficacy, Alvotech's innovative research and development strategies underline its commitment to replicating complex biologics, ensuring they are more affordable without compromising on safety and effectiveness. Alvotech’s business model is intricately woven into the fabric of collaboration and partnership. Rather than attempting to market its products independently, Alvotech aligns with a network of global partners for commercialization and distribution, allowing the company to reach diverse markets efficiently. This approach not only widens their reach but also minimizes the cost and time associated with entering new geographical territories. Alvotech generates revenue by selling these biosimilars, capitalizing on the expiration of patents on original biologic drugs. In doing so, it provides healthcare providers and patients with cost-effective options, positioning itself as a valuable player in the increasingly essential biosimilar market.

ALVO Intrinsic Value
10.132 USD
Undervaluation 47%
Intrinsic Value
Price
A
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
7.6%
=
Operating Income
$43.4m
/
Revenue
$573.4m
What is Alvotech SA's current Operating Margin?

The current Operating Margin for Alvotech SA is 7.6%, which is above its 3-year median of -216.4%.

How has Operating Margin changed over time?

Over the last 3 years, Alvotech SA’s Operating Margin has increased from -407.5% to 7.6%. During this period, it reached a low of -562.4% on Sep 30, 2023 and a high of 14.2% on Dec 31, 2024.

Back to Top